Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 39

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 39
---
     (1,262)
  
    Total external costs 
     4,160  
     5,138  
     10,192  
     12,483 
  
    Internal costs 
     1,644  
     1,915  
     3,251  
     3,263 
  
    Total 
    $5,804  
    $7,053  
    $13,443  
    $15,746 

We typically use our employee
resources across our development programs. We track outsourced development costs by product candidate or development program, but we do
not allocate internal costs personnel costs including salaries and stock-based compensation to specific product candidates or development
programs.

We
participate, through our wholly owned subsidiary in Australia, in the Australian research and development tax incentive program, such
that a percentage of our qualifying research and development expenditures are reimbursed by the Australian government, and such incentives
are reflected as a reduction of research and development expense. The Australian research and development tax incentive is recognized
when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the
consideration can be reliably measured. 

We
participate, through our wholly owned subsidiary in the United Kingdom, in the research and development program provided by the United
Kingdom tax relief program, such that a percentage of our qualifying research and development expenditures are reimbursed by the United
Kingdom government, and such incentives are reflected as a reduction of research and development expense. The United Kingdom research
and development tax incentive is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure
has been incurred and the amount of the consideration can be reliably measured.

29

Substantially all our research
and development expenses to date have been incurred in connection with our current and future product candidates. We expect our research
and development expenses to increase significantly for the foreseeable future as we advance an increased number of our product candidates
through clinical development, including the conduct of our planned clinical trials and manufacturing drug to be used in those clinical
trials. The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. The successful
development of product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs required
to complete the remaining development of any product candidates. This is due to the numerous risks and uncertainties associated with the
development of